Table 3 Clinicopathological features of seven ovarian metastatic lung adenocarcinoma
From: ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
Case | Age (years) | Smoking history | Side | Tumor size (cm) | Surgery | Gross appearance | Morphological features | Interval time between primary lung cancer and matastasis to ovary and concurrent metastatic sites | ALK (D5F3) | ALK-FISH | EGFRstatus | KRAS status | Targeted treatment | Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
LTO_1 | 43 | N/A | U | L,11*7*3 | TAH-BSO | solid, with minor honeycomb cut-section | solid | 30 m, no concurrent sites | Positive | Rearrangement | Neg. | Neg. | No | 10 m, DOD |
LTO_2 | 39 | no | B | L,4*4*3;R,4*3*2 | TAH-BSO and omentectomy | solid | acinar | 5 m, no concurrent sites | negative | No | exon 19 mutation | Neg. | Gefitinib | 13 m, DOD |
LTO_3 | 52 | no | U | L, 21.5*18*8 | TAH-BSO | Cystic prominent, focal solid area | Acinar+solid | Synchronous, bone, left supraclavicular lymph node | negative | No | Neg. | Neg. | No | 36 m, alive |
LTO_4 | 50 | N/A | U | L,16*15*6 | USO | solid and cystic section, focal papillary architeched | acinar | 6 m, brain and bone | Positive | Rearrangement | Neg. | Neg. | No | 19 m, alive |
LTO_5 | 56 | no | B | R, 8.5*5*4.5;L, 3*2*1 | BSO + appendectomy | solid, | acinar | 19 m, bone | Positive | Rearrangement | Neg. | Neg. | No | 22 m, alive |
LTO_6 | 35 | no | U | / | TAH-BSO | / | solid predominant | Synchronous, brain and bone | Positive | Rearrangement | Neg. | Neg. | Crizotinib | 24 m, alive |
LTO_7 | 55 | no | U | R, 14*10*9 | / | Cystic with old dark brown viscous liguid | acinar | 7 m, liver | negative | No | Neg. | Neg. | No | 8 m, DOD |
LTO_8(10) | 54 | 2.5-pack year | B | R, 2–4.1 L, 2.7–5 | BSO | / | Thick trabeculae or solid nests | 1.2 m, brain | Positive | Rearrangement | Neg. | Neg. | No | / |
LTO_9[11] | 39 | 1-pack per day | B | 15 by 10 | Left salpingo-oophorectomy+right ovarian cystectomy | Half cystic and half solid, filled with old blood in cyst and slightly yellow and white solid tissue with small cysts | acinar | 20 m, brain | / | Rearrangement | / | / | / | 28 m, alive |
LTO_10[12] | 50 | / | B | 12.8*12.2*11.7 | TAH-BSO | Mixed cystic and solid adnexal mass | Solid with Intracytoplasmic mucinous and signet-ring cells | 39 m, liver and bone | / | Rearrangement | Neg. | / | Crizotinib | / |
LTO_11[13] | 38 | No | U | L | / | / | / | Synchronous, bone | / | Neg. | exon 21 mutation |  | Erlotinib | 24 m, DOD |
LTO_12[13] | 47 | / | U | R | BSO | solid | solid predominant | 20 m, right supraclavicular lymph node | / | Rearrangement | Neg. | / | Crizotinib | 12 m, alive |
LTO_13[14] | 33 | No | U | L:7.9*6.9 | Adnexal mass biopsy | solid | acinar | Synchronous, bilateral supraclavicular lymph node | Positive | / | Neg. | / | Crizotinib | 4 m, alive |
LTO_14[15] | 41 | No | U | L: 10 | Left salpingo-oophorectomy | solid | acinar | 8 m, pleural | / | Rearrangement | Neg. | Neg. | Crizotinib | 10 m, alive |
LTO_15[16] | 45 | No | U | R:11 | TAH-BSO | Solid | Solid nests with abundant granular and extensive signet ring cell change | 48 m, no concurrent sites | / | / | Mutation in lung cancer | / | / | 1 m, DOD |
LTO_16[17] | 37 | No | U | L: 9*5.8 | No resection | Mixed solid and cysts | Acinar and several signet-ring cells | Synchronous, brain | Pos. in lung cancer | Rearrangment in lung cancer | / | / | Alectinib | 20 m, alive |